Cannabis for Nausea & Chemotherapy in Australia — What Works & How to Access (2026)

Nausea and vomiting are among the most feared and most common side effects of chemotherapy, affecting up to 80% of patients who receive emetogenic (nausea-inducing) chemotherapy agents. Despite major advances in antiemetic pharmacology over the past two decades — 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), and corticosteroids (dexamethasone) — chemotherapy-induced nausea and vomiting (CINV) remains inadequately controlled in a substantial proportion of patients.

For this group, medicinal cannabis represents one of the most evidence-supported adjunct interventions available. Nausea is also one of the most commonly approved indications for medicinal cannabis prescriptions in Australia — and one of the few where a synthetic cannabinoid (nabilone) has been in clinical use for decades.

This guide covers all forms of nausea where cannabis has evidence — not just chemotherapy — and provides practical guidance on how to access legal treatment in Australia.

Types of nausea where cannabis may help

Chemotherapy-induced nausea and vomiting (CINV)

CINV occurs in two phases:

• Acute CINV: Occurs within 24 hours of chemotherapy. Better controlled by modern antiemetics.
• Delayed CINV: Peaks 2–5 days after chemotherapy. Harder to control with standard antiemetics and where cannabis shows the most added benefit.
• Anticipatory CINV: Develops as a conditioned response, with nausea occurring before chemotherapy starts — triggered by the sights, smells or routines associated with treatment. Primarily a conditioned anxiety response; CBD’s anxiolytic effects may specifically help this type.
• Refractory CINV: Nausea uncontrolled despite standard antiemetic regimens. Cannabis is most commonly used in this scenario.

Other medical nausea

Beyond chemotherapy, cannabis has evidence for nausea in:

• HIV/AIDS-related nausea and appetite loss — one of the original approved indications for dronabinol (synthetic THC)
• Radiation therapy-induced nausea — similar mechanism to CINV
• Opioid-induced nausea — cannabinoids may reduce opioid-related nausea while maintaining analgesia
• Gastric motility disorders (gastroparesis) — though evidence here is more limited
• Pregnancy-related nausea — cannabis is contraindicated in pregnancy; hyperemesis gravidarum requires specialist treatment, not cannabis

How cannabis works as an antiemetic

The nausea and vomiting reflex is controlled by the vomiting centre in the brainstem (specifically the medulla), with input from the gastrointestinal tract and the chemoreceptor trigger zone (CTZ). CB1 receptors are expressed throughout these regions — in the dorsal vagal complex, the nucleus tractus solitarius and the gastrointestinal wall.

THC acts as a CB1 agonist, directly suppressing the nausea and vomiting reflex through multiple pathways:

1. Central suppression: CB1 agonism in the brainstem vomiting centre reduces the sensitivity of the nausea and vomiting reflex to emetogenic signals
2. Peripheral effect: CB1 receptors in the gut wall regulate gastric motility and reduce vagal nausea signalling
3. Dopaminergic modulation: THC affects dopaminergic signalling in the CTZ, with additional antiemetic action
4. Anxiolytic effect: For anticipatory CINV (where anxiety is the trigger), both THC’s anxiolytic effect at low doses and CBD’s consistent anxiolytic action reduce the conditioned nausea response

CBD contributes through different mechanisms:

• 5-HT1A agonism: CBD activates serotonin receptors in the dorsal vagal complex — the same type of receptor targeted by ondansetron (Zofran). This produces antiemetic effects through a complementary pathway to THC
• TRPV1 desensitisation: Reduces peripheral emetogenic signalling
• Anxiolytic effect: Particularly relevant for anticipatory nausea

What the clinical evidence shows

Cochrane Review (2015): The most comprehensive systematic review of cannabis for CINV examined 23 randomised controlled trials involving 1,326 participants. Findings: cannabinoids were more effective than placebo for CINV and were generally comparable to prochlorperazine, metoclopramide and domperidone (older antiemetics). The evidence for cannabinoids versus modern 5-HT3 antagonists (ondansetron) was less clear, with the latter often producing fewer side effects. Conclusion: cannabis is a legitimate adjunct antiemetic, particularly for refractory CINV.

Nabilone (Cesamet): A synthetic THC analogue with a longer half-life and more consistent dosing than plant-derived THC. Multiple RCTs have demonstrated nabilone’s efficacy for acute and delayed CINV. It has been in clinical use since the 1980s and is still prescribed in Australia under the SAS-B framework for refractory CINV.

THC:CBD combinations: More recent research suggests that combining THC with CBD may produce better antiemetic outcomes than THC alone — the entourage effect producing broader spectrum antiemetic action. Nabiximols (Sativex) has been studied in this context with positive results in some trials.

Cannabis vs conventional antiemetics: where does it fit?

Antiemetic	Best for	Limitations	Cannabis advantage
Ondansetron (Zofran)	Acute CINV	Less effective for delayed CINV	Better for delayed CINV
Aprepitant (Emend)	Delayed CINV	Expensive; drug interactions	Lower cost; broader effect
Dexamethasone	Both phases	Steroid side effects with repeated use	No steroid side effects
Prochlorperazine	Acute nausea	Extrapyramidal side effects	Fewer movement-related side effects
Cannabis (THC/CBD)	Delayed and refractory CINV; anticipatory CINV	Psychoactive effects (THC); variable delivery	Addresses appetite + mood + sleep simultaneously; useful for refractory cases

The clinical recommendation across most Australian oncology settings: Use standard antiemetic regimens as first-line; add cannabis for refractory CINV (inadequate control with standard treatment), delayed CINV (>24 hours after chemotherapy), or where the simultaneous benefits for appetite, mood and sleep are clinically valuable.

Choosing the right product for nausea

THC oil or capsule (most effective for CINV)

Best for: Chemotherapy-related nausea, delayed CINV, appetite loss

Timing: Take 1–2 hours before chemotherapy infusion; continue every 6–8 hours for the first 48–72 hours after infusion (the delayed CINV window).

Starting dose: 2.5mg THC. This is the dose range at which antiemetic benefit is most consistent and side effects (dizziness, sedation, psychoactive effects) are minimised. Increase to 5mg if insufficient benefit.

Key principle: The antiemetic effect of THC does not require high doses. Higher doses do not produce proportionally better nausea control and significantly increase psychoactive side effects, dizziness and sedation — particularly problematic in already debilitated patients.

CBD oil (for anticipatory and anxiety-driven nausea)

Best for: Anticipatory CINV, anxiety-driven nausea, complementary to THC

CBD used in the days before chemotherapy reduces the anticipatory anxiety that drives conditioned anticipatory nausea. Take CBD morning and evening in the 3–4 days before each chemotherapy cycle. Maintain alongside THC during the acute and delayed CINV window.

Starting dose: 50–100mg CBD twice daily.

Vaporised THC (for acute breakthrough nausea)

Best for: Rapid relief of acute nausea episodes; useful when oral administration is difficult due to active nausea

Onset: 5–10 minutes — the fastest-acting format. For patients who are actively vomiting and cannot hold an oral dose, vaporised THC is the most practical format.

Important: Smoking cannabis is inappropriate for immunocompromised chemotherapy patients. Use a clean dry herb vaporiser at 170–185°C only. Even with vaporising, consider the pulmonary infection risk in neutropenic patients — discuss with your oncologist.

Sublingual THC:CBD oil (balanced rapid onset)

Holding a balanced oil under the tongue for 60–90 seconds before swallowing produces faster onset than swallowed oil (15–30 minutes) while delivering a consistent, measured dose. This is the preferred format for patients who experience moderate nausea but can hold a sublingual dose.

Nausea product timing guide

CINV type	When to take cannabis	Best product
Preventing acute CINV	1–2 hours before chemotherapy	THC oil (swallowed); CBD oil for anticipatory anxiety
Managing acute CINV during infusion	As needed during 0–24 hours post-chemo	Vaporised THC (if clinically appropriate); sublingual oil
Preventing delayed CINV	Every 6–8 hours for 48–72 hours post-chemo	THC oil or capsule (sustained release)
Anticipatory CINV	3–4 days before each cycle	CBD-dominant oil morning and evening
Breakthrough nausea (any phase)	As needed	Vaporised THC

Drug interactions with chemotherapy

Both THC and CBD inhibit cytochrome P450 enzymes (primarily CYP3A4, CYP2C9 and CYP2D6), which metabolise many chemotherapy drugs. This can raise blood levels of some agents, potentially increasing both efficacy and toxicity.

Chemotherapy drugs with known CYP3A4 dependence include: Cyclophosphamide, paclitaxel, docetaxel, etoposide, imatinib, erlotinib.

Practical guidance:

• Always tell your oncologist you are using cannabis — this is essential safety information
• Your oncologist may adjust chemotherapy dose timing or add monitoring in response
• The benefit of cannabis for refractory CINV typically outweighs the manageable interaction risk in most cases
• CBD has greater interaction potential than THC due to its more potent CYP enzyme inhibition

Cannabis interactions with common antiemetics (ondansetron, aprepitant, dexamethasone) are not clinically significant at typical medicinal doses.

Side effects of cannabis antiemetics

Side effect	THC	CBD	Management
Dizziness	Common at higher doses	Rare	Reduce THC dose; take lying down
Sedation	Common	Minimal	Time doses around rest periods
Psychoactive effect (“high”)	Present; less at low doses	None	Use lowest effective dose; add CBD
Dry mouth	Moderate	Mild	Stay hydrated; ice chips
Increased heart rate	Moderate	Minimal	Monitor; avoid in cardiac patients without GP advice
Anxiety/paranoia	Risk at high doses	Rare	Keep THC ≤5mg; use CBD alongside
Memory impairment	Dose-dependent	None	Use during rest periods, not when needing alertness

How to access medicinal cannabis for nausea in Australia

Nausea is one of the most straightforwardly approved indications for medicinal cannabis in Australia. Your oncologist, GP or a telehealth platform can prescribe under the TGA’s SAS-B framework.

Through your oncologist: Most Australian oncologists are now familiar with medicinal cannabis for CINV. Raise it specifically at your next appointment — bring details of your current antiemetic regimen and which aspects of nausea remain inadequately controlled.

Through your GP: If your oncologist prefers you manage cannabis through primary care, your GP can prescribe under SAS-B with a brief clinical note from your oncologist confirming your chemotherapy regimen.

Through telehealth platforms: Alternaleaf, Polln and Leafio can typically arrange consultations within 24–48 hours. Bring documentation of your cancer diagnosis, current chemotherapy protocol and antiemetic regimen.

Cost: $100–200/month for most antiemetic cannabis regimens. Not PBS-listed. Cancer patients receiving palliative care should ask about specific support programs — ask your palliative care team.

Frequently asked questions

Is cannabis an effective antiemetic for chemotherapy nausea? Yes — particularly for delayed CINV (2–5 days post-chemotherapy) and refractory CINV (inadequately controlled despite standard antiemetics). THC’s direct CB1-mediated suppression of the vomiting reflex is well-established. Cannabis is most effective as an adjunct to, not a replacement for, modern antiemetics like ondansetron and aprepitant.

Can I use cannabis if I am on ondansetron (Zofran)? Yes — there is no significant pharmacokinetic interaction between cannabis and ondansetron. They work through different mechanisms and can be used together. Cannabis may specifically help with delayed CINV, where ondansetron is less effective.

What is the best cannabis product for chemotherapy nausea? A low-dose THC oil (2.5–5mg THC) taken before and consistently after chemotherapy is the most evidence-based approach. Vaporised THC provides faster relief for breakthrough nausea. CBD alongside THC improves antiemetic effect while reducing psychoactive side effects. Discuss timing and dosing with your oncologist or medicinal cannabis prescriber.

Can cannabis cause nausea itself? Yes — at very high THC doses, cannabis can cause or worsen nausea. This is most common in heavy, chronic cannabis users who develop cannabinoid hyperemesis syndrome (CHS) — a condition characterised by cyclic vomiting in people who use very large amounts of cannabis daily. At therapeutic antiemetic doses (2.5–10mg THC), this risk is very low.

Is nabilone (Cesamet) the same as cannabis? Nabilone is a synthetic analogue of THC — it produces similar antiemetic effects through CB1 receptor agonism but is a synthetic pharmaceutical, not a plant-derived product. It has a longer, more consistent duration of action than plant THC and is available by prescription in Australia under SAS-B. For some patients, nabilone’s predictable pharmacology is preferred over plant-derived THC oils.

Can cannabis help with nausea from radiation therapy? Yes. Radiation-induced nausea and vomiting shares the same mechanism as CINV (emetogenic stimulus triggering the brainstem vomiting reflex) and responds similarly to cannabis antiemetic treatment. The same products and dosing principles apply.

How quickly does cannabis work for nausea? Vaporised THC produces antiemetic effects within 5–15 minutes. Sublingual (under-tongue) oils work in 15–30 minutes. Swallowed oils and capsules take 45–90 minutes. For planned chemotherapy-induced nausea, swallowed oils taken 1–2 hours before infusion provide the most sustained coverage.

Do I need to tell my oncologist I am using cannabis for nausea? Yes — absolutely. Cannabis interacts with CYP450 enzymes that metabolise some chemotherapy drugs. Your oncologist needs this information for your safety. In Australia, most oncology intake forms now ask about cannabis use. Disclosure is protective, not penalising.